Fetal anemia monitoring with middle cerebral artery Doppler

Fetal anemia is a potentially serious complication in pregnancy, but it can often be detected before the fetus develops hydrops or other visible signs of compromise. The main non-invasive surveillance method is Doppler assessment of the middle cerebral artery peak systolic velocity, commonly abbreviated to MCA-PSV. It estimates how quickly blood is moving through a key cerebral vessel and can indicate reduced blood viscosity caused by anemia.

This approach has changed care for pregnancies affected by red-cell alloimmunisation, including anti-D and anti-c antibodies. It is also useful when anemia may follow parvovirus B19 infection, fetomaternal haemorrhage, twin-to-twin transfusion complications or other fetal conditions. The scan does not measure haemoglobin directly, so its result must be interpreted alongside gestational age, maternal history, ultrasound findings and the clinical setting.

For Australian families, referral pathways can differ between a public tertiary hospital, a private obstetric practice and an outer-metropolitan or rural service. A patient in Sydney, Melbourne or Brisbane may have access to a fetal medicine unit on the same day, while someone in regional Western Australia or northern Queensland may need coordinated travel, telehealth review and a local ultrasound appointment. Early communication between services reduces delays when a result needs specialist assessment.

The former FAOPS 2020 congress archive reflects the wider perinatal and neonatal research community in which fetal surveillance is discussed. Although the Tokyo meeting was cancelled during the COVID-19 pandemic, its subject areas remain relevant to clinicians working across maternal-fetal medicine, obstetrics, neonatology and perinatal research.

What the Doppler measurement shows

The middle cerebral artery supplies the fetal brain. When fetal haemoglobin falls, the blood becomes less viscous and the fetus increases cardiac output to preserve oxygen delivery to vital organs. These changes can produce a higher peak systolic velocity in the MCA. The measurement is therefore an indirect marker of fetal anaemia rather than a direct blood count.

Clinicians usually express the result as multiples of the median, or MoM, adjusted for gestational age. A value around 1.0 MoM is close to the expected median for that gestation. An MCA-PSV at or above approximately 1.5 MoM is widely treated as a significant warning threshold, particularly in pregnancies with a known risk of fetal anaemia. Local protocols and the overall clinical picture still matter.

A raised velocity should not be interpreted in isolation. Fetal movement, breathing, head position, insonation angle, machine settings and operator experience can influence the reading. A technically difficult scan may need to be repeated by an experienced sonographer before decisions are made.

When surveillance becomes important

Serial MCA Doppler is particularly valuable after maternal red-cell antibodies have been identified. The antibody level, its specificity and previous pregnancy history help determine whether the fetus is at meaningful risk. A prior pregnancy affected by severe haemolytic disease or intrauterine transfusion generally warrants early involvement from a fetal medicine team.

Other indications include suspected congenital infection, parvovirus B19 exposure, unexplained fetal hydrops, a significant fetomaternal haemorrhage and complications in monochorionic twin pregnancies. Reduced fetal movements, abnormal ultrasound findings or a sudden change in fetal wellbeing may also prompt broader assessment, though MCA-PSV is only one part of that evaluation.

Routine Doppler screening for every pregnancy is not usually appropriate. In a low-risk pregnancy, testing is guided by symptoms, antibody results or a specific clinical concern. Care also needs to account for conditions that affect pregnancy monitoring more broadly. Practical information about disrupted services and gestational diabetes guidance illustrates why appointments, pathology and ultrasound plans should be coordinated rather than managed as separate tasks.

How the scan is performed

The patient generally lies in a semi-reclined position while an ultrasound probe is placed on the abdomen. The sonographer obtains a standard axial view of the fetal head, identifies the circle of Willis and samples the MCA close to its origin from the internal carotid artery. The angle between the ultrasound beam and blood flow should be kept as close to zero degrees as possible.

Several consistent waveforms are recorded during a period when the fetus is still. Pressure on the fetal head, fetal breathing, active movement and an incorrect sample location can produce an unreliable value. The report should record gestational age, the measured velocity, MoM, technical limitations and comparison with earlier examinations.

The test is painless and does not expose the fetus to ionising radiation. It may be completed during a regular antenatal ultrasound appointment, although a concerning result usually requires review by a maternal-fetal medicine specialist. In Australia, private imaging clinics may provide the scan, but escalation pathways should be agreed with the referring obstetric team before testing takes place.

Understanding the 1.5 MoM threshold

An MCA-PSV above 1.5 MoM increases concern for moderate or severe fetal anaemia, but it is not an automatic diagnosis. False-positive results can occur, particularly later in pregnancy, when the relationship between velocity and haemoglobin becomes less reliable. Results close to the threshold are often checked with repeat testing, careful technique and review of the trend.

The rate of change can be as important as a single number. A steady rise in a sensitised pregnancy may require more urgent action than a stable value below the threshold. Clinicians also consider hydrops, cardiomegaly, placental abnormalities, growth, amniotic fluid, fetal movements and the estimated gestational age.

MCA-PSV becomes less dependable after about 35 weeks, although it can still contribute to decision-making. At that stage, the balance may shift towards delivery, depending on fetal maturity, the severity and cause of the suspected anaemia, the availability of neonatal care and the time needed to arrange an intrauterine procedure.

Responding to an abnormal result

When the result is unexpectedly high, the first step is usually confirmation by an experienced operator or specialist service. Maternal blood testing may clarify antibody levels, while ultrasound checks for hydrops, enlarged cardiac chambers, placental thickening and fluid accumulation. Additional investigations can include infection testing or evaluation for fetomaternal haemorrhage.

If significant anaemia is likely before a safe gestational age for birth, fetal blood sampling and intrauterine transfusion may be considered in a specialist centre. The transfusion is performed under ultrasound guidance and uses carefully matched, specially prepared red cells. Some fetuses need more than one transfusion, so surveillance continues after treatment.

If the pregnancy is sufficiently advanced, planned birth may be safer than another invasive procedure. The decision involves obstetricians, fetal medicine specialists, neonatologists, transfusion staff and the family. It should include discussion of corticosteroids when appropriate, timing of birth, neonatal resuscitation and the likely need for phototherapy or exchange transfusion after delivery.

Causes beyond red-cell antibodies

Maternal alloimmunisation remains a major reason for MCA surveillance. Anti-D prophylaxis has reduced RhD disease substantially, but sensitisation still occurs, and other antibodies such as anti-c and anti-K can cause clinically important fetal disease. Anti-K can be particularly difficult because the severity of anaemia may not correlate reliably with the antibody concentration.

Parvovirus B19 can suppress fetal red-cell production and may lead to severe anaemia even when maternal illness was mild or unnoticed. The risk is assessed using maternal serology, timing of infection and serial fetal ultrasound. A specialist may monitor the MCA velocity for several weeks after infection because fetal complications can develop after the initial exposure.

In a twin pregnancy, unequal blood flow through placental vascular connections can create anaemia in one fetus and excess red-cell concentration in the other. MCA Doppler can support assessment, but it does not replace fluid measurements, bladder views, growth assessment and specialist review. The same principle applies to suspected bleeding: a normal scan cannot always exclude a recent or evolving haemorrhage.

Coordinating care in Australia

Australian care may involve a general practitioner, midwife, obstetrician, sonographer, pathology provider and tertiary fetal medicine unit. Public hospital referral systems can be different from private booking arrangements, and Medicare funding does not remove the need to confirm whether a particular scan, consultation or travel expense is covered. Families should receive a clear contact point for urgent changes such as reduced fetal movement or bleeding.

Geography matters. A woman living outside Adelaide, Perth, Darwin or Hobart may need to travel to a capital-city service for invasive testing or intrauterine transfusion. Accommodation, work, childcare and transport can affect whether appointments are practical. Scheduling serial scans together with antenatal visits can make monitoring more manageable, particularly when heat, long driving distances or limited public transport add strain.

Documentation and privacy are also important. Results may move between public and private providers, so consent and secure information-sharing should follow Australian privacy requirements, including obligations under the Privacy Act 1988 and relevant state or territory health laws. Decisions about fetal therapy, neonatal treatment and pregnancy continuation must respect informed consent and the legal framework where the patient is receiving care.

When very early birth is possible, fetal anaemia management intersects with neonatal ethics and counselling. Discussions should be individualised rather than based on a single gestational-age rule; resources on ethical prematurity decisions provide useful context for the shared decision-making involved. The aim is a coordinated plan that covers monitoring, transfer, birth, transfusion and newborn treatment.

MCA-PSV surveillance works best when it is treated as a pathway rather than a standalone ultrasound number. Ensure that at-risk pregnancies are identified early, arrange serial Doppler with experienced providers, and refer promptly when velocity rises, symptoms appear or technical limitations make the result uncertain. A written plan shared between the family, local clinicians and the tertiary team can help deliver timely, safer care.